Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Alanzi, Meshaal, Abu-Tineh, Mohammad, Szabados, Lajos, Sharaf Eldean, M Z, Alatasi, Sali, Taha, Ruba Y, Elkourashy, Sarah A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961566/
https://www.ncbi.nlm.nih.gov/pubmed/36852093
http://dx.doi.org/10.2147/OTT.S394193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961566/
https://www.ncbi.nlm.nih.gov/pubmed/36852093
http://dx.doi.org/10.2147/OTT.S394193

Ejemplares similares